Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 11/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021126 | 0.95 | CYP19A1 (0.48) | CYP19A1HRH4HRH3ADRB2GBA1 | |
| SCHEMBL3542321 | 0.94 | GBA1 (0.49) | CYP19A1HRH4HRH3ADRB2GBA1 | |
| SCHEMBL12641729 | 0.94 | GBA1 (0.49) | CYP19A1HRH4HRH3ADRB2GBA1 | |
| SCHEMBL9926315 | 0.92 | HRH4 (0.51) | CYP19A1HRH4HRH3GBA1 | |
| SCHEMBL20375486 | 0.91 | HRH4 (0.56) | CYP19A1HRH4HRH3GBA1 | |
| SCHEMBL3533937 | 0.90 | CYP19A1 (0.51) | CYP19A1HRH4HRH3ADRB2GBA1 | |
| SCHEMBL3434883 | 0.90 | HRH4 (0.45) | CYP19A1HRH4HRH3ADRB2GBA1 | |
| SCHEMBL3436123 | 0.90 | HRH4 (0.42) | HRH4HRH3ADRB2GBA1 | |
| SCHEMBL18489327 | 0.89 | HRH4 (0.57) | CYP19A1HRH4HRH3GBA1 | |
| SCHEMBL10079149 | 0.89 | HRH4 (0.57) | CYP19A1HRH4HRH3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20200369728-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-10300109-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-9957296-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20130072439-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | NASH HUW M | 2011-10-13 | — | — | US | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | CYP19A1 3353/4885HRH4 3864/4885HRH3 3432/4885 |
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | TCF4, CTNNB1, WNT1 | CYP19A1 3554/4885HRH4 1260/4885HRH3 1800/4885 |
| US-20130072439-A1 | PEPTIDOMIMETIC MACROCYCLES | TCF4, WNT1, CTNNB1 | CYP19A1 3129/4885HRH4 1310/4885HRH3 2149/4885 |
| US-20200369728-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | NGLY1, BID, DNPEP | CYP19A1 2283/4885HRH4 2561/4885HRH3 2159/4885 |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | SLC29A2, SLC29A1, SLC22A3 | CYP19A1 4772/4885HRH4 4816/4885HRH3 3990/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | CYP19A1 3250/4885HRH4 4246/4885HRH3 3700/4885 |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | PCNA, MKI67, NFATC1 | CYP19A1 2887/4885HRH4 3022/4885HRH3 2281/4885 |
| US-10300109-B2 | Peptidomimetic macrocycles | TCF4, CTNNB1, WNT1 | CYP19A1 3554/4885HRH4 1260/4885HRH3 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.